Following 28 days of combination
dosing with RO5024048, PEG-IFN, and RBV, patients will be dosed an additional 28 days (through Day 56 of the study) with just PEG-IFN, and RBV. After completing 56 days under this study, patients who participate in Part 3 will be optionally enrolled into a standard of care protocol with PEG-IFN and RBV, to be conducted by Roche. Patients who opt to enroll into the standard of care protocol will be given up to 40 weeks of PEG-IFN and RBV.